Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 58

1.

Trypanosoma brucei: Inhibition of cathepsin L is sufficient to kill bloodstream forms.

Steverding D, Rushworth SA, Florea BI, Overkleeft HS.

Mol Biochem Parasitol. 2019 Nov 16;235:111246. doi: 10.1016/j.molbiopara.2019.111246. [Epub ahead of print]

PMID:
31743688
2.

ROS-mediated PI3K activation drives mitochondrial transfer from stromal cells to hematopoietic stem cells in response to infection.

Mistry JJ, Marlein CR, Moore JA, Hellmich C, Wojtowicz EE, Smith JGW, Macaulay I, Sun Y, Morfakis A, Patterson A, Horton RH, Divekar D, Morris CJ, Haestier A, Di Palma F, Beraza N, Bowles KM, Rushworth SA.

Proc Natl Acad Sci U S A. 2019 Dec 3;116(49):24610-24619. doi: 10.1073/pnas.1913278116. Epub 2019 Nov 14.

3.

CD38-Driven Mitochondrial Trafficking Promotes Bioenergetic Plasticity in Multiple Myeloma.

Marlein CR, Piddock RE, Mistry JJ, Zaitseva L, Hellmich C, Horton RH, Zhou Z, Auger MJ, Bowles KM, Rushworth SA.

Cancer Res. 2019 May 1;79(9):2285-2297. doi: 10.1158/0008-5472.CAN-18-0773. Epub 2019 Jan 8.

PMID:
30622116
4.

Acute myeloid leukemia induces protumoral p16INK4a-driven senescence in the bone marrow microenvironment.

Abdul-Aziz AM, Sun Y, Hellmich C, Marlein CR, Mistry J, Forde E, Piddock RE, Shafat MS, Morfakis A, Mehta T, Di Palma F, Macaulay I, Ingham CJ, Haestier A, Collins A, Campisi J, Bowles KM, Rushworth SA.

Blood. 2019 Jan 31;133(5):446-456. doi: 10.1182/blood-2018-04-845420. Epub 2018 Nov 6.

PMID:
30401703
5.

Targeting the KEAP1/NRF2 pathway to manipulate the expression of oncogenic and oncosuppressive miRNAs in human leukemia.

Bowles KM, Rushworth SA.

Mol Cell Oncol. 2018 Apr 19;5(3):e988484. doi: 10.4161/23723556.2014.988484. eCollection 2018.

6.

PGC-1α driven mitochondrial biogenesis in stromal cells underpins mitochondrial trafficking to leukemic blasts.

Marlein CR, Zaitseva L, Piddock RE, Raso-Barnett L, Scott MA, Ingham CJ, Collins A, Bowles KM, Rushworth SA.

Leukemia. 2018 Sep;32(9):2073-2077. doi: 10.1038/s41375-018-0221-y. Epub 2018 Jul 20. No abstract available.

PMID:
30030506
7.

Myeloma-derived macrophage inhibitory factor regulates bone marrow stromal cell-derived IL-6 via c-MYC.

Piddock RE, Marlein CR, Abdul-Aziz A, Shafat MS, Auger MJ, Bowles KM, Rushworth SA.

J Hematol Oncol. 2018 May 16;11(1):66. doi: 10.1186/s13045-018-0614-4.

8.

HIF1α drives chemokine factor pro-tumoral signaling pathways in acute myeloid leukemia.

Abdul-Aziz AM, Shafat MS, Sun Y, Marlein CR, Piddock RE, Robinson SD, Edwards DR, Zhou Z, Collins A, Bowles KM, Rushworth SA.

Oncogene. 2018 May;37(20):2676-2686. doi: 10.1038/s41388-018-0151-1. Epub 2018 Feb 28.

PMID:
29487418
9.

Pulling the plug - halting cancer's theft of mitochondria.

Marlein CR, Zaitseva L, Rushworth SA.

Oncoscience. 2017 Nov 2;4(11-12):173-174. doi: 10.18632/oncoscience.374. eCollection 2017 Nov. No abstract available.

10.

NADPH oxidase-2 derived superoxide drives mitochondrial transfer from bone marrow stromal cells to leukemic blasts.

Marlein CR, Zaitseva L, Piddock RE, Robinson SD, Edwards DR, Shafat MS, Zhou Z, Lawes M, Bowles KM, Rushworth SA.

Blood. 2017 Oct 5;130(14):1649-1660. doi: 10.1182/blood-2017-03-772939. Epub 2017 Jul 21.

PMID:
28733324
11.

Front-line glioblastoma chemotherapeutic temozolomide is toxic to Trypanosoma brucei and potently enhances melarsoprol and eflornithine.

Steverding D, Rushworth SA.

Exp Parasitol. 2017 Jul;178:45-50. doi: 10.1016/j.exppara.2017.05.006. Epub 2017 May 25.

PMID:
28552794
12.

Inflammatory Differences in Plaque Erosion and Rupture in Patients With ST-Segment Elevation Myocardial Infarction.

Chandran S, Watkins J, Abdul-Aziz A, Shafat M, Calvert PA, Bowles KM, Flather MD, Rushworth SA, Ryding AD.

J Am Heart Assoc. 2017 May 3;6(5). pii: e005868. doi: 10.1161/JAHA.117.005868.

13.

The Role of PI3K Isoforms in Regulating Bone Marrow Microenvironment Signaling Focusing on Acute Myeloid Leukemia and Multiple Myeloma.

Piddock RE, Bowles KM, Rushworth SA.

Cancers (Basel). 2017 Mar 28;9(4). pii: E29. doi: 10.3390/cancers9040029. Review.

14.

The bone marrow microenvironment - Home of the leukemic blasts.

Shafat MS, Gnaneswaran B, Bowles KM, Rushworth SA.

Blood Rev. 2017 Sep;31(5):277-286. doi: 10.1016/j.blre.2017.03.004. Epub 2017 Mar 12. Review.

PMID:
28318761
15.

PI3Kδ and PI3Kγ isoforms have distinct functions in regulating pro-tumoural signalling in the multiple myeloma microenvironment.

Piddock RE, Loughran N, Marlein CR, Robinson SD, Edwards DR, Yu S, Pillinger GE, Zhou Z, Zaitseva L, Auger MJ, Rushworth SA, Bowles KM.

Blood Cancer J. 2017 Mar 10;7(3):e539. doi: 10.1038/bcj.2017.16.

16.

Leukemic blasts program bone marrow adipocytes to generate a protumoral microenvironment.

Shafat MS, Oellerich T, Mohr S, Robinson SD, Edwards DR, Marlein CR, Piddock RE, Fenech M, Zaitseva L, Abdul-Aziz A, Turner J, Watkins JA, Lawes M, Bowles KM, Rushworth SA.

Blood. 2017 Mar 9;129(10):1320-1332. doi: 10.1182/blood-2016-08-734798. Epub 2017 Jan 3.

PMID:
28049638
17.

MIF-Induced Stromal PKCβ/IL8 Is Essential in Human Acute Myeloid Leukemia.

Abdul-Aziz AM, Shafat MS, Mehta TK, Di Palma F, Lawes MJ, Rushworth SA, Bowles KM.

Cancer Res. 2017 Jan 15;77(2):303-311. doi: 10.1158/0008-5472.CAN-16-1095. Epub 2016 Nov 21.

18.

Targeting PI3Kδ and PI3Kγ signalling disrupts human AML survival and bone marrow stromal cell mediated protection.

Pillinger G, Loughran NV, Piddock RE, Shafat MS, Zaitseva L, Abdul-Aziz A, Lawes MJ, Bowles KM, Rushworth SA.

Oncotarget. 2016 Jun 28;7(26):39784-39795. doi: 10.18632/oncotarget.9289.

19.

Trypanocidal and cysteine protease inhibitory activity of isopentyl caffeate is not linked in Trypanosoma brucei.

Steverding D, da Nóbrega FR, Rushworth SA, de Sousa DP.

Parasitol Res. 2016 Nov;115(11):4397-4403. Epub 2016 Aug 18.

PMID:
27535679
20.

Activity of Bruton's tyrosine-kinase inhibitor ibrutinib in patients with CD117-positive acute myeloid leukaemia: a mechanistic study using patient-derived blast cells.

Rushworth SA, Pillinger G, Abdul-Aziz A, Piddock R, Shafat MS, Murray MY, Zaitseva L, Lawes MJ, MacEwan DJ, Bowles KM.

Lancet Haematol. 2015 May;2(5):e204-11. doi: 10.1016/S2352-3026(15)00046-0. Epub 2015 Apr 14.

PMID:
26688095
21.

Targeting BTK for the treatment of FLT3-ITD mutated acute myeloid leukemia.

Pillinger G, Abdul-Aziz A, Zaitseva L, Lawes M, MacEwan DJ, Bowles KM, Rushworth SA.

Sci Rep. 2015 Aug 21;5:12949. doi: 10.1038/srep12949.

22.

Oxidative stress responses and NRF2 in human leukaemia.

Abdul-Aziz A, MacEwan DJ, Bowles KM, Rushworth SA.

Oxid Med Cell Longev. 2015;2015:454659. doi: 10.1155/2015/454659. Epub 2015 Mar 30. Review.

23.

Ibrutinib inhibits BTK-driven NF-κB p65 activity to overcome bortezomib-resistance in multiple myeloma.

Murray MY, Zaitseva L, Auger MJ, Craig JI, MacEwan DJ, Rushworth SA, Bowles KM.

Cell Cycle. 2015;14(14):2367-75. doi: 10.1080/15384101.2014.998067. Epub 2015 Jan 7.

24.

NRF2-driven miR-125B1 and miR-29B1 transcriptional regulation controls a novel anti-apoptotic miRNA regulatory network for AML survival.

Shah NM, Zaitseva L, Bowles KM, MacEwan DJ, Rushworth SA.

Cell Death Differ. 2015 Apr;22(4):654-64. doi: 10.1038/cdd.2014.152. Epub 2014 Oct 17.

25.

Ibrutinib inhibits SDF1/CXCR4 mediated migration in AML.

Zaitseva L, Murray MY, Shafat MS, Lawes MJ, MacEwan DJ, Bowles KM, Rushworth SA.

Oncotarget. 2014 Oct 30;5(20):9930-8.

26.

Understanding life and death decisions in human leukaemias.

MacEwan DJ, Barrera LN, Keadsanti S, Rushworth SA, Shah NM, Yuan T, Zaitseva L.

Biochem Soc Trans. 2014 Aug;42(4):747-51. doi: 10.1042/BST20140127.

PMID:
25109952
27.

Identification of Bruton's tyrosine kinase as a therapeutic target in acute myeloid leukemia.

Rushworth SA, Murray MY, Zaitseva L, Bowles KM, MacEwan DJ.

Blood. 2014 Feb 20;123(8):1229-38. doi: 10.1182/blood-2013-06-511154. Epub 2013 Dec 4.

PMID:
24307721
28.

Ibrutinib in relapsed chronic lymphocytic leukemia.

Rushworth SA, MacEwan DJ, Bowles KM.

N Engl J Med. 2013 Sep 26;369(13):1277-8. doi: 10.1056/NEJMc1309710. No abstract available.

PMID:
24066760
29.

Understanding the role of NRF2-regulated miRNAs in human malignancies.

Shah NM, Rushworth SA, Murray MY, Bowles KM, MacEwan DJ.

Oncotarget. 2013 Aug;4(8):1130-42. Review.

30.

Attenuation of dexamethasone-induced cell death in multiple myeloma is mediated by miR-125b expression.

Murray MY, Rushworth SA, Zaitseva L, Bowles KM, Macewan DJ.

Cell Cycle. 2013 Jul 1;12(13):2144-53. doi: 10.4161/cc.25251. Epub 2013 Jun 11.

31.

The high Nrf2 expression in human acute myeloid leukemia is driven by NF-κB and underlies its chemo-resistance.

Rushworth SA, Zaitseva L, Murray MY, Shah NM, Bowles KM, MacEwan DJ.

Blood. 2012 Dec 20;120(26):5188-98. doi: 10.1182/blood-2012-04-422121. Epub 2012 Oct 17.

PMID:
23077289
32.

BTK inhibitor ibrutinib is cytotoxic to myeloma and potently enhances bortezomib and lenalidomide activities through NF-κB.

Rushworth SA, Bowles KM, Barrera LN, Murray MY, Zaitseva L, MacEwan DJ.

Cell Signal. 2013 Jan;25(1):106-12. doi: 10.1016/j.cellsig.2012.09.008. Epub 2012 Sep 11.

PMID:
22975686
33.

Bortezomib induces heme oxygenase-1 expression in multiple myeloma.

Barrera LN, Rushworth SA, Bowles KM, MacEwan DJ.

Cell Cycle. 2012 Jun 15;11(12):2248-52. doi: 10.4161/cc.20343. Epub 2012 Jun 15.

34.

Understanding the role of miRNA in regulating NF-κB in blood cancer.

Rushworth SA, Murray MY, Barrera LN, Heasman SA, Zaitseva L, Macewan DJ.

Am J Cancer Res. 2012;2(1):65-74. Epub 2011 Nov 21.

35.

Chemical vapor deposition kinetics and localized growth regimes in combinatorial experiments.

Dabirian A, Kuzminykh Y, Wagner E, Benvenuti G, Rushworth SA, Hoffmann P.

Chemphyschem. 2011 Dec 23;12(18):3524-8. doi: 10.1002/cphc.201100637. Epub 2011 Oct 11. No abstract available.

PMID:
21990203
36.

Micro RNAs as a new therapeutic target towards leukaemia signalling.

Murray MY, Rushworth SA, MacEwan DJ.

Cell Signal. 2012 Feb;24(2):363-8. doi: 10.1016/j.cellsig.2011.09.021. Epub 2011 Sep 25. Review.

PMID:
21978953
37.

Protection of acute myeloid leukaemia cells from apoptosis induced by front-line chemotherapeutics is mediated by haem oxygenase-1.

Heasman SA, Zaitseva L, Bowles KM, Rushworth SA, Macewan DJ.

Oncotarget. 2011 Sep;2(9):658-68.

38.

TNF mediates the sustained activation of Nrf2 in human monocytes.

Rushworth SA, Shah S, MacEwan DJ.

J Immunol. 2011 Jul 15;187(2):702-7. doi: 10.4049/jimmunol.1004117. Epub 2011 Jun 13. Erratum in: J Immunol. 2011 Dec 1;187(11):6160.

39.

Silencing FLIP(L) modifies TNF-induced apoptotic protein expression.

Zaitseva L, Rushworth SA, MacEwan DJ.

Cell Cycle. 2011 Apr 1;10(7):1067-72. Epub 2011 Apr 1.

PMID:
21403465
40.
41.

High basal nuclear levels of Nrf2 in acute myeloid leukemia reduces sensitivity to proteasome inhibitors.

Rushworth SA, Bowles KM, MacEwan DJ.

Cancer Res. 2011 Mar 1;71(5):1999-2009. doi: 10.1158/0008-5472.CAN-10-3018. Epub 2011 Jan 6.

42.

The role of nrf2 and cytoprotection in regulating chemotherapy resistance of human leukemia cells.

Rushworth SA, Macewan DJ.

Cancers (Basel). 2011 Mar 29;3(2):1605-21. doi: 10.3390/cancers3021605.

43.
44.

NF-kappaB-inhibited acute myeloid leukemia cells are rescued from apoptosis by heme oxygenase-1 induction.

Rushworth SA, Bowles KM, Raninga P, MacEwan DJ.

Cancer Res. 2010 Apr 1;70(7):2973-83. doi: 10.1158/0008-5472.CAN-09-3407. Epub 2010 Mar 23.

45.

Molecular crosstalk between TRAIL and natural antioxidants in the treatment of cancer.

Rushworth SA, Micheau O.

Br J Pharmacol. 2009 Aug;157(7):1186-8. doi: 10.1111/j.1476-5381.2009.00266.x.

47.

Epigallocatechin activates haem oxygenase-1 expression via protein kinase Cdelta and Nrf2.

Ogborne RM, Rushworth SA, O'Connell MA.

Biochem Biophys Res Commun. 2008 Sep 5;373(4):584-8. doi: 10.1016/j.bbrc.2008.06.068. Epub 2008 Jun 27.

48.

TNF signaling gets FLIPped off: TNF-induced regulation of FLIP.

Rushworth SA, Taylor A, Langa S, MacEwan DJ.

Cell Cycle. 2008 Jan 15;7(2):194-9. Epub 2007 Oct 12.

PMID:
18256533
49.

HO-1 underlies resistance of AML cells to TNF-induced apoptosis.

Rushworth SA, MacEwan DJ.

Blood. 2008 Apr 1;111(7):3793-801. doi: 10.1182/blood-2007-07-104042. Epub 2008 Jan 17.

PMID:
18202225
50.

Curcumin: potential for hepatic fibrosis therapy?

O'Connell MA, Rushworth SA.

Br J Pharmacol. 2008 Feb;153(3):403-5. Epub 2007 Nov 26.

Supplemental Content

Loading ...
Support Center